Abstract
BACKGROUND Limited data exist on how SARS-CoV-2 enters and spreads in the general population.
METHODS In Iceland we used two strategies for SARS-CoV-2 testing. Targeted testing was conducted in individuals at high risk of being infected (n=4,551) who were symptomatic, had traveled to high-risk areas, or been in contact with infected individuals, and a population screening was performed of those who accepted an offer of free testing (n=5,502). We sequenced the genomes of SARS-CoV-2 from 340 positive individuals to establish the origin of the virus, how it spreads and mutates in the population.
RESULTS On March 22 2020, 528 had tested positive for SARS-CoV-2 in the targeted testing group (11.6%) and 50 in the population screening group (0.9%, 95% CI: 0.7%-1.2%). This represents approximately 0.2% of the Icelandic population. Large fractions of the individuals who tested positive in both testing groups had traveled outside Iceland (38.4% and 34.0%, respectively). A smaller fraction of those under 10 years of age is positive than among all tested: 2.8% vs 12.3% for targeted testing (P=1.6e-9) and 0.0% vs 1.0% for population screening (P=0.031). Relatively fewer females were positive in the targeted testing than males (9.5% vs 14.6%, P=6.8e-9). SARS-CoV-2 in Iceland came from eight diverse clades, seven A clades and one B clade. The composition of clades was different between the two testing groups and changed with time. In the early targeted testing the main clades or 65.0% were A2a1 and A2a2 derived from skiing areas in Italy and Austria, respectively, but those reduced in frequency to 30.6% in the later targeted testing group and were overtaken by the A1a and A2a clades, the two most common clades in the population screening group.
CONCLUSION SARS-CoV-2 has spread widely in the Icelandic population outside of the high-risk groups targeted for testing by the healthcare system. Several different strains of the virus cause these infections and the composition of known infections in Iceland changed rapidly. Children and females are less vulnerable to SARS-CoV-2 than adults and males. Hence, to contain the pandemic we must increase the scope of the testing.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No external funding.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All sequenced virus genomes have been deposited into GISAID.
